tirzepatide and bone density Tirzepatide, a dual GLP-1 GIP receptor agonist, promotes loss in obese mice via gut microbial-related metabolites Does Tirzepatide Cause Osteoporosis? Evidence

One theory, he said, is that because the medications suppress appetite, some patients may not get enough key nutrients, such as vitamin D and calcium, which are important for maintaining bone health

Abdominal injections typically offer more consistent depth due to thicker fatty tissue

Continuous glucose monitors, insulin pump therapy, and structured education programmes can all help reduce hypoglycaemia risk and the anxiety around it

Hunt JN, Stubbs DF

Liraglutide has been shown to decrease IL-17 and cytokines induced by TNF- which play a role in the pathogenesis of HS

These compounded medications may also be misbranded based on incorrectly labeled strengths